Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Status:
Recruiting
Trial end date:
2021-08-05
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label study to evaluate different methods of initiating tenapanor
therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate
binder naïve or on phosphate binder therapy. The objective to evaluate the effect of
tenapanor alone or in combination with phosphate binders to achieve target serum phosphorus
(s-P) levels of ≤5.5 mg/dL when tenapanor is administered as the core therapy (alone or in
combination with phosphate binders) for the treatment of hyperphosphatemia in patients with
chronic kidney disease (CKD) on dialysis.